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The purpose of this study was to investigate the relationship between selective 
serotonin reuptake inhibitor (SSRI) medication on auditory skills in clinically depressed 
subjects. Experimental subjects prescribed an SSRI were tested in a medicated and an 
unmedicated condition, and the test results were compared. Furthermore, the 
experimental group was compared with a control group consisting of normal subjects. 
Test measures included pure tone audiometry, tympanometry, acoustic reflex thresholds, 
and auditory electrophysiologic measures such as auditory brainstem and auditory late 
responses. An assessment scale for depression (Beck Depression Inventory-II) was also 
used. Results indicated statistically significant differences for the BDI-II between the 
control and experimental groups for both conditions. Electrophysiologic measures 
indicated a significantly shorter latency for auditory late potential P1 at 55 dBnSL, and a 
significantly larger amplitude at 45 dBnSL for the N1/P2 component for the unmedicated 
group. Although the other measures showed trends, they did not reach significance.  
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   CHAPTER 1
INTRODUCTION 
 
Neurotransmitters are chemicals released by the axon of a neuron into a space 
located between the axon and adjacent neuron called the synaptic cleft.   These chemicals 
either bind to the adjacent neuron to provide an excitatory or inhibitory response, or get 
oxidized and taken up by the presynaptic cell for resynthesis of that chemical.   Serotonin 
(5-hydroxytryptamine, 5-HT), a biogenic amine, is a classical neurotransmitter, widely 
dispersed in the central nervous system as well as in the peripheral nervous system.   
Presynaptic and postsynaptic actions of 5-HT occurring in the peripheral, enteric 
(intestine), and central nervous systems include hyperpolarization, depolarization, and 
potentiation of norepinephrine and dopamine release, potentiation and inhibition of 
acetylcholine release, and regulation of vascular tone (Vandermalen, 1985).   Serotonin is 
both an excitatory and inhibitory neurotransmitter used by the auditory system to 
facilitate sensory information processing (Jacobs & Fornal, 1993).   The various actions 
of 5-HT in the brain and periphery can manifest as disorders when disrupted.   They can 
be expressed as affective disorders or disorders disruptive to a particular sensory system.     
Some disorders related to serotonin include depression, obsessive-compulsive disorders, 
hyperacusis, migraine headaches, and other psychiatric disorders (Hegerl et al., 1998).   
Research conducted by Thompson et al. (1994) found that many 5-HT receptor 
subtypes were located in the auditory system including the cochlear nucleus as well as the 
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inferior colliculus of the brainstem.   They concluded that since the auditory system is 
innervated by many serotonergic fibers and terminal endings, 5-HT may modulate central 
auditory processing by tonic inhibition of acoustic pathways.   Patients with migraines 
who also have symptoms of hyperacusis were described in their research as evidence of 
5-HT in the auditory system, which functions as a regulator of primary sensory pathways.   
Many patients with these disorders also exhibit a low concentration of serotonin in 
plasma and also platelets of the blood (Sarrias et al., 1987).   Treatment of serotonin 
disorders by use of selective serotonin reuptake inhibitors (SSRIs) is common in the 
United States as well as in other countries.   This research addressed the effects of SSRI 
on auditory measures in patients with unipolar depression. 
 A case study exhibiting the auditory effects of serotonin was documented by 
Gopal et al. (2000).   A female subject with clinical symptoms of hyperacusis, difficulty 
understanding speech, withdrawn depression, lethargy, as well as hypersensitivity to 
touch, pressure and light was evaluated in both an unmedicated and medicated condition.   
The medicated condition consisted of treatment by an SSRI that supposedly blocks the 
mechanism for reuptake of serotonin back into the presynaptic neuron, and therefore 
allows a higher concentration of serotonin to accumulate in the postsynaptic cleft.   This 
patient was evaluated over the course of 18 months using auditory processing tests, 
evoked potentials, impedance testing, otoacoustic emissions, and uncomfortable loudness 
measures.   Significant differences were observed between medicated and unmedicated 
conditions for transient evoked otoacoustic emissions, uncomfortable loudness levels, 
and auditory processing skills as reflected in the SCAN-A (A screening test for auditory 
processing in adolescence and adults.) test scores.  Further research relating SSRI and 
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auditory processing abilities of clinically depressed patients was recommended for a 
larger sample of patients with similar clinical symptoms.    
    Carney (2001) further investigated the role of SSRIs on peripheral and lower 
brainstem auditory processing.    Clinically depressed subjects taking SSRI (medicated 
condition) were compared with depressed subjects not taking any SSRI  (unmedicated 
condition).   A control group of subjects that neither exhibited an affective disorder nor 
had taken any SSRI medication was also used in the study.   Tests included in Carney’s 
research were uncomfortable loudness measures (UCL), otoacoustic emissions with 
contralateral masking, masking level difference (MLD), acoustic reflexes, intensity 
resolution, and temporal integration.   Although statistical significance was not reached 
when comparing these three groups, a general trend toward lower UCL, and a smaller 
dynamic range was observed in the unmedicated group when compared to the medicated 
and control groups.    Acoustic reflex thresholds did not show significant differences 
between the three groups.   The unmedicated group also showed a smaller difference 
limen for intensity as compared with the control and medicated groups.   Masking level 
difference showed a trend for a smaller release from masking in unmedicated subjects as 
compared to control and medicated subjects.   The Beck Depression Inventory-II, 
however, showed statistical significant difference between both experimental groups and 
the control group.   It was recommended that comparison be made between the test 
results obtained during medicated and unmedicated conditions for the same set of 
subjects.    
 In a related study, Bishop (2001) investigated the role of SSRI on the central 
auditory system.   Auditory brainstem response (ABR), auditory late response (ALR), 
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and auditory tests using speech stimuli were compared between control, unmedicated, 
and medicated subjects.   The loudness dependence of ABR for peak V is described by 
Hegerl et al., (1993) as an increase in amplitude with intensity increase, showed 
significant differences between unmedicated subjects and control subjects as did the –20 
message to competing ratio (MCR) condition on the Synthetic Sentence Identification 
test (SSI).   Other electrophysiology measures such as absolute latency for peak V, the 
amplitude increase for the N1/P2 component of the ALR, and the right ear scores for the -
20 MCR condition of the SSI were not significant but showed a trend between the 
unmedicated and control groups.   It was suggested that intra-subject comparison and a 
larger sample size be used for further studies.    
Goals of the Study 
 This study investigated the role of SSRI medication on auditory measures using 
intra-subject comparison.   Experimental subjects who were clinically depressed were 
tested in a medicated and unmedicated condition.   This group consisted of subjects 
diagnosed by a physician as clinically depressed according to the criteria as set forth by 
the referring physician and the DSM IV (Diagnostic and Statistics Manual for Mental 
Disorders-IV), then treated with one of the five SSRIs that included Prozac, Zoloft, 
Celexa, Paxil, or Luvox.   A control group consisting of normal subjects was also 
evaluated that neither had a history of depression nor was taking any SSRI medication.   
Tests used in this study were otoscopy, tympanometry, pure-tone thresholds, acoustic 
reflexes, amplitude resolution, auditory brainstem response (ABR), and auditory late 
response (ALR).   These tests measure the integrity of the auditory system and can reveal 
the function of the auditory system at several different levels.   The Beck Depression 
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Inventory-II was used to quantify the depressive symptoms of each patient and to assess 
correlation with the other tests used. 
Specific questions of this study include: 
1) Were there significant differences in acoustic reflex thresholds and amplitude 
resolution test results between medicated and unmedicated conditions of the 
experimental group? 
2) Were there significant latency and amplitude differences between ALR waves P1 
and N1 and ABR peak V between medicated and unmedicated conditions of the 
experimental group?  
3) Were there significant differences in any of the test measures between the control 


















REVIEW OF LITERATURE 
 
   
Prelude 
 Each auditory measure used in this research is related to some aspect of serotonin 
in the brain.   Research on depression and serotonin is extensive, however, the specific 
effects they have on the auditory system is more obscure.   The relationship between 
serotonin and how it functions to regulate auditory information will be described by 
relevant research as well as the effects a disruption of serotonin may have on auditory 
processing.    
 The tests selected in this research measure auditory function and will be described 
from peripheral to central.   Tests reviewed for this research are acoustic reflex 
thresholds, amplitude resolution, auditory brainstem response, and auditory late response.   
The Beck Depression Inventory-II also included in this study is a scale which measures 
depression and is relevant is assessing the presence of depression in individuals in the 
experimental group.   The tests selected for this research are widely available and are 









 Serotonin (5-hydroxytryptamine; 5-HT) is a neurotransmitter found in the 
vertebrate central nervous system and is categorized as a biogenic amine synthesized in 
the indole nucleus and therefore further classified as an indolemine (Vandermaelen, 
1985).   Neurotransmitters function as messengers that facilitate excitatory or inhibitory 
responses by acting on postsynaptic receptors.   Currently up to seven receptor classes 
have been identified and within these classes, receptor subtype classes have been 
recognized as well (Martin & Humphrey, 1994).   Uphouse (1997) suggested the 
importance of multiple receptor subtypes might provide advantage to certain species by 
allowing flexibility, which enables the nervous system to receive and integrate 
information more efficiently than would be possible with only one receptor subtype.   
The various actions of 5-HT such as regulation of sleep-wake-arousal cycle (Jacobs & 
Fornal, 1999; Imeri et al., 2000), motor output (Jacobs & Fornal, 1993), inhibition of 
sensory information (Stutzmann et al., 1998), regulation of cerebral blood flow 
(Vandermaelen, 1985), and regulation of temperature (Vandermaelen, 1985; Imeri et al., 
2000) are examples of the influence this neurotransmitter has on various functions.   Most 
all of the 5-HT cell bodies occur in the raphe nuclei of the brainstem or near the midline 
and were associated with functions such as controlling trunk and proximal limb muscles 
(Jacobs & Fornal, 1999), though 5-HT receptors also occur in areas of the brain which 
regulate mood and anxiety (Martin & Humphrey, 1994).   Serotonergic neurons innervate 
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all levels of the central nervous system (Vandermaelen, 1985) and there is evidence that 
5-HT is involved in similar excitatory and inhibitory roles in the auditory system. 
 
Serotonin in the Auditory System 
 Thompson et al., (1994) described in three mammalian species the presence and 
relative density of 5-HT in the brainstem auditory nuclei.   Thompson and colleagues 
noted that the presence of serotonin in these structures might play a modulatory role in 
the primary sensory pathways such as tonic inhibition of the acoustic reflex.   It was 
further added that 5-HT should be considered when evaluating auditory pathophysiology.   
Fitzgerald and Sanes (1999) observed direct evidence of 5-HT innervation of the auditory 
nuclei specifically the lateral superior olive (LSO), which is the primary site of binaural 
convergence of the afferent auditory fibers.   They also concluded that 5-HT may play a 
modulatory role in the auditory system.    
 Evidence of serotonin in the cortical auditory system is found in the augmenting 
reducing effect of the N1/P2 component of the ALR.   The ALR is generated by the 
primary auditory cortex (Pantev et al., 1990) or Broadman’s areas 41 and 42 (Brown et 
al., 1979).   This area is greatly innervated by serotonergic neurons and is therefore rich 
in serotonin synthesis like most sensory areas (Brown et al., 1979).   The auditory cortex 
has the highest synthesis rate and cortical concentration of serotonin out of all the sensory 
processing centers of the brain (Azmitia & Gannon, 1986; Lewis et al., 1986).   Patients 
who show lower levels of serotonin have larger amplitudes of the N1/P2 component, 
which are pronounced at higher intensities (Hegerl et al., 1998; Juckel et al., 1999).    
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 Several studies have shown 5-HT to be a factor in the manifestation of auditory 
disorders in humans, such as hyperacusis (Marriage & Barnes, 1995; Gopal et al., 2000), 
tinnitus (Simpson & Davies, 2000), and auditory processing disorders (Gopal et al., 
2000).   Patients presenting with clinical symptoms of depression also exhibit symptoms 
related to the auditory system.    
 Hyperacusis is described by Marriage and Barnes (1995) as an unusual 
hypersensitivity or discomfort induced by exposure to sound.   They categorize 
hyperacusis as a separate phenomenon to recruitment, which is an abnormal loudness 
growth usually associated with peripheral hearing loss.   Hyperacusis like tinnitus 
therefore cannot be measured objectively and may be under reported when it occurs 
concurrently with other pathologies such as tinnitus and headache.   As compared with 
recruitment, hyperacusis occurs in patients with normal hearing.   Hyperacusis is often 
concurrent with photophobia and tinnitus, which are often present with other disorders 
related to 5-HT dysfunction or dysregulation.   Marriage and Barnes (1995) conclude on 
the basis of research and clinical evidence that the primary cause of central hyperacusis is 
related to 5-HT function.    
 
Disorders Related to Serotonin 
 Disorders related to the serotonergic system include obesity, compulsive disorders 
such as alcoholism and bulimia, and depression (Lucas, 1992).   The presence of major 
depression in the general population ranges from 4-9% affecting 10 % of men and 20 % 
of women at some point in their lives (Alarcon, et al. 1998).   Depression is an illness that 
is often chronic and recurrent affecting 12% of the treated population for as long as 5 
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years with some people experiencing relapses up to ten years after treatment (Hirschfeld, 
1994).   Depression is often difficult to diagnose and treat because the course of illness 
can be variable (Geringer & Wool, 1994) and symptoms can be masked by physical 
complaints and often coexist with other medical problems (Alarcon et al., 1998).    
 Diagnosis of depression by primary care physicians and psychiatrists is achieved 
systematically using criteria set forth by the Diagnostic and Statistics Manual of Mental 
Disorders-IV (DSM-IV).   Major depressive disorders must fit the criteria for a depressed 
mood or loss of interest that lasts for at least two weeks and is accompanied by at least 
four additional symptoms of depression.   Some symptoms of depression as specified by 
the DSM-IV include loss of appetite, insomnia, agitation, decreased energy, feeling 
worthless or fatigued, and loss of interest or pleasure.   Depression may also be 
accompanied by other disorders such as eating disorders, disorders of anxiety or panic, or 
depression exhibiting specific features such as psychotic episodes or seasonal patterns of 
onset. 
 Patients suffering from depression, obsessive-compulsive disorders, and other 
psychiatric disorders are commonly treated with serotonin reuptake inhibitors (SSRIs) 
(Hegerl et al., 1998; Bruder et al., 2001).   SSRI medications act by blocking the reuptake 
mechanism for reabsorption of serotonin in the presynaptic cleft therefore allowing more 
accumulation of the neurotransmitter (Fuller & Wong, 1990; Pinder, 1997).   SSRIs and 
polycyclics are two major categories of antidepressants (Geringer & Wool, 1994).   
However, SSRIs are more commonly prescribed because they carry fewer side effects 
and have a high safety profile when taken alone in an overdose situation (Geringer & 
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Wool, 1994) as compared to the mortality rate of 70-80% associated with overdose of 
polycyclic antidepressants (Alarcon et al., 1998). 
  It has been observed by several researchers that patients exhibiting symptoms of 
affective disorders also have lower levels of serotonin in the blood (Sarrias et al., 1987; 
Perez et al., 1998).   The amine hypothesis of depression describes the underlying 
malfunction of this illness as related to the depletion or dysregulation of norepinephrine 
and/or serotonin in the brain (Geringer & Wool, 1994).    This decrease in the production 
and possible abnormalities in the uptake by receptors are found to be closely associated 
with depression (Geringer & Wool, 1994).    The decrease in serotonin levels can be 
treated and help alleviate the symptoms related to this dysfunction.   SSRIs act to inhibit 
the reuptake of 5-HT allowing accumulation of 5-HT in the synaptic cleft of the 
presynaptic neuron (Fuller & Wong, 1990; Pinder, 1997). 
  Patients with depression who also have pathological auditory symptoms such as 
hyperacusis, auditory processing disorders, and tinnitus show benefit from these 
medications.    A patient treated with an SSRI showed a greater dynamic range by 
elevation of the uncomfortable loudness level (UCL), reduced transient evoked 
otoacoustic emissions, improved auditory processing, and alleviation of hyperacusic 
symptoms (Gopal et al., 2000).   Treatment of serotonin related disorders with SSRI 
medication has a direct effect on tests related to hearing and auditory processing. 
 
Acoustic Reflex Thresholds 
 The acoustic reflex threshold (ART) is the contraction of the stapedius 
muscle located in the middle ear to sufficiently loud stimuli.   Contraction of the 
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stapedius muscle occurs both ipsilaterally and contralaterally to acoustic stimulation.   
The pathway for the ipsilateral response begins in cochlea and is transmitted by the 
auditory nerve to the ipsilateral ventral cochlear nucleus (Thompson, 1983).   The 
majority of these pathways pass through the medial part of the facial motor nucleus and 
then travel down the facial nerve, which is innervated by the stapedius muscle attached to 
the ossicles of the middle ear.   Contralateral contraction of the stapedius is due to the 
decussating pathway of the medial superior olive in the brainstem, which then follows the 
contralateral pathway of the facial motor nucleus to the facial nerve, then innervating the 
stapedius muscle of the contralateral ear.   (Jerger, 1970) 
 The acoustic reflex threshold is a widely accepted measure of auditory pathway 
integrity and can be incorporated into a protocol sensitive for retrocochlear pathology 
(Bauch et al., 1983).   Patients with normal auditory function typically present with 
normal ARTs.   Patients with facial nerve and vestibulocohlear nerve lesion often have 
absent reflexes as do patients with middle ear pathologies (Jerger, 1970; Marriage & 
Barnes, 1995; Hunter et al., 1999).   Elderly patients with normal hearing show elevated 
acoustic reflex thresholds when elicited by a broadband stimulus  (Gelfand & Piper, 
1981).    
 
Amplitude Resolution 
 The detection of difference in small changes in intensity of a signal is often 
referred to as amplitude resolution (Fastl and Schorn, 1981).   Suprathreshold tests, such 
as discrimination between loudness of tones, are diagnostically relevant because sounds 
of life are generally above threshold (Fastl and Schorn, 1981).   Level discrimination can 
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be measured with either modulated or pulsed tones.   Fastl and Schorn (1981) explained 
that this difference in stimulus produces different results, which are related to the 
underlying processing mechanism.   The modulated tone creates an excitation pattern 
along the basilar membrane that is constant and when changed by an increase in intensity 
will immediately be detected by the auditory centers of the brain.   Pulsed tones however, 
involve more auditory processing because the excitation pattern of the tone must be 
stored then compared to the second tone.   Fastl and Schorn (1981) reasoned that pulsed 
tones require higher centers of the auditory pathway than modulated tones. 
 
Auditory Brainstem Response 
 The auditory brainstem response (ABR) measures the integrity of the auditory 
pathway from the VIIIth nerve to the midbrain (Moller et al. 1981, 1982).   Wave I and II 
of the ABR is generated in the peripheral auditory system while wave III is generated by 
the cochlear nucleus and the trapezoid body of the brainstem while waves IV and V are 
generated by the superior olivary complex and the lateral lemniscus respectively (Moller 
et al. 1981, 1982).   Auditory evoked potentials are used to measure several areas of the 
auditory pathway and can be grouped by latency.   Latency describes the time interval 
from the onset of stimulus and the generation of the evoked potential waveform. 
 The ABR occurs within 10 ms following the onset of the stimulus.   The ABR can 
be used to estimate hearing thresholds and assess the integrity of the auditory system 
(Galambos & Hecox, 1978).   Many factors influence the ABR including age and gender.   
The ABR is also influence by neurotransmitter transmission including serotonin 
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(Bhargava et al., 1981).   This is evident when disorders related to serotonin are studied 
using auditory evoked potentials. 
  Knott et al. (1994) showed brainstem involvement in panic disorder as an 
increase in amplitudes of waves III and V.   Latencies however where unaffected.    Nolfe 
et al. (1998) showed patients with obsessive-compulsive disorders to have significantly 
increased interpeak latencies between I-V for the right ear as compared with controls.   
They also showed significant in a decrease in amplitude of wave III as compared with 
controls.    
 
Auditory Late Response 
 The auditory late response occurs between 150 & 300 ms and is generated by the 
primary auditory cortex (Hegerl & Juckel, 1993).   Three main landmarks may be 
observed at these latencies; P1, N1, and P2.   The amplitude stimulus intensity function or 
ASF slope describes an increase in amplitude as intensity increases (Hegerl & Juckel, 
1993).   The ASF slope is proposed to be a direct result of decreased serotonergic 
transmission (Hegerl & Juckel, 1993) and an increase in serotonergic activity results in a 
decrease in the ASF slope (Juckel et al., 1999).   Hegerl and Juckel (1993) indicated 
serotonin as the primary neurotransmitter for this effect as this slope is greatly enhanced 
by reduced central serotonergic neurotransmission.   This research suggests that the 
intensity dependence of the N1/P2 component may be a noninvasive way to diagnose low 
serotonin levels.   Juckel et al. (1999) proposes that event related potentials such as the 
ALR could be used to more effectively treat patients with disorders of the serotonergic 
system by identifying them more efficiently and treating them more specifically. 
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 Dierks et al., (1999) found that the intensity dependence of AEP’s is not an 
indicator of central serotonergic activity.   This was shown by manipulating the levels of 
central serotonergic activity indirectly, by decreasing the levels of tryptophan, which is 
necessary for the synthesis of serotonin.   The decrease in tryptophan in the central 
nervous system has shown to decrease the levels of serotonin in animal and human 
studies using positron emission topography (PET) scans (Nishizawa et al., 1998).   By 
decreasing the level of tryptophan and therefore serotonin synthesis.   Dierks and his 
colleagues should have seen the same intensity dependence of N1/P2 as the research 
conducted by Hegerl (1993).   However, they observed reduced intensity dependence as a 
result of low tryptophan levels.   Debener et al., (2002) showed a similar result in 
research that compared a depletion of tryptophan group to a placebo group.   They also 
found that depletion of tryptophan is not related to the ASF slope and therefore does not 
reflect central serotonergic transmission.   How this relationship is directly related to low 
tryptophan or whether serotonin is affected at a later stage in the process is not clear.    
 Event related potentials are affected by disorders related serotonergic dysfunction 
such as migraine (Sand & Vingren, 2000), panic disorder (Knott et al., 1994), 
schizophrenia (Lindstrom et al., 1990), and obsessive-compulsive disorder (Nolfe et al., 
1998).   There is evidence that medications and their effects can be observed in event 
related potentials as well (Roon et al., 1999; Hegerl et al., 1992; Bruder et al., 2001).   
However, controversy suggests more research needs to be done in this area. 
 Concu et al., (1977), described effects of low 5-HT levels on latency in auditory 
evoked potentials in rats.   The 5-HT levels of the brain were decreased by injection of p-
chlorophenylalanine (PCPA), which selectively inhibits tryptophan necessary for 5-HT 
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synthesis.   When the levels of cerebral 5-HT were reduced in the rat brain, the latencies 
were also markedly reduced.   An increase in the levels of cerebral 5-HT showed an 
increase in latency.   They explained that the primary function of serotonin in the brain is 
to inhibit responses in the afferent pathway.   A decrease in cerebral 5-HT will cause the 
central acoustic pathway to be less inhibited and exhibiting less control over the response.    
 Auditory evoked potentials are an objective method for examining the auditory 
pathway and can give indirect information about the mechanisms that affect the integrity 
of that pathway.   Other measures such as ARTs, pure-tone thresholds, and amplitude 
resolution can give information about the auditory system but they tell little about the 
perception and state of mind of the patient.   Self-report scales are often widely used 
when assessing depression in individuals, and are valuable when correlated to other 
objective measures.    
 
Beck Depression Inventory II 
 The Beck Depression Inventory, originally introduced in 1961, is used in 
evaluating depressive symptoms in psychiatric patients as well as in normal populations.   
It is also one of the most widely used instruments in evaluating the severity of depressive 
symptoms (Whisman et al., 2000).   The value of this instrument for evaluating patients 
with affective disorders lies in its high internal consistency among items despite the 
broad range of cognitive, affective, behavioral, and somatic symptoms thought to reflect 
the complexities of depression (Killgore, 1999).   This inventory was updated to the Beck 
Depression Inventory-II (BDI-II) to reflect the diagnostic criteria for major depressive 
disorders as described by the DSM-IV (Steer et al., 1999). 
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 The BDI-II is a self report inventory that assesses how a person has been feeling 
for the “last two weeks including today” according to the criteria set forth by the DSM-
IV for major depressive episodes (Steer et al., 1999).   The BDI-II is composed of 21 
symptoms such as agitation, worthlessness, concentration difficulty, and loss of energy.   
Each of these symptoms is rated on a four-point scale ranging from 0-3, with the highest 
possible score being 63 (Steer et al., 1999).   According to this scale, a score of 0-12 
indicates minimal depression, 13-19 indicated mild depression, 20-28 indicates moderate 
depression, and 29-63 indicates severe depression. 
 The tests chosen for this research are widely used in clinical and research 
environments because they are easy to administer and have high internal validity.   
Serotonin is evident to be a contributor in disorders affecting the central nervous system.   
Some disorders related to serotonin also have auditory symptoms that compromise 
processing abilities of auditory information.   Research in the area of serotonin related to 
auditory processing is necessary to because many patients are treated with SSRI 
medication.   This research intends to add to a growing body of knowledge that is 










 All Groups 
 Thirty-five paid volunteers participated in this study, 17 in the control group and 
18 in the experimental group.   They were recruited from advertisements in the North 
Texas Daily newspaper, referrals from physicians, advertisements on the North Texas 
Television station (NTTV), as well as flyers placed around campus. 
 All subjects completed an informed consent explaining the procedures and tests, a 
case history, Beck Depression Inventory-II, and authorization for students to administer 
the testing.    All subjects exhibited type A tympanograms.   Each research participant 
was informed of confidentiality measures taken to maintain the integrity of a clinical 
research environment. 
 This project was sponsored by the Texas Advanced Research program, awarded 
to Dr. Kamakshi Gopal.    
 Inclusion Criteria for the Control Group 
 Subjects in the control group were included only if they had not taken an anti-
depressant medication, had not been previously diagnosed with depression, or had ever 
been diagnosed with any mental illness related to serotonin including other affective 
disorders.   All control subjects had normal hearing (American Academy of 
Ophthalmology and Otolaryngology, 1979).    
18
 
 Inclusion Criteria for Experimental Group 
 The experimental group consisted of subjects diagnosed with depression as 
specified by the criteria set forth by the prescribing physician and DSM-IV, followed by 
a prescription of one of the five SSRI medications; fluoxetine hydrochloride (Prozac), 
sertraline hydrochloride (Zoloft), paroxetine (Paxil), citalopram (Celexa), or fluvoxamine 
(Luvox).   The experimental subjects were tested once when they were unmedicated for 
at least one month and the second time when they were on an SSRI for at least a month.    
  Subjects with history of head injury or other serious illnesses contraindicated to 
auditory or cognitive performance, or subjects taking any other central nervous system 
medication were not included in the study.   Those subjects who were diagnosed with 
depression but not currently taking medication were included in the study and were first 
tested for the unmedicated round of testing.   After they completed the unmedicated 
round these same subjects were re-tested when they began taking the SSRI for at least 
one month as prescribed by a physician.   The once month period between testing 
sessions for the experimental group was based on the SSRI with the longest half-life, 
which is fluoxetine (Prozac) that has a half-life of 7-8 days. 
 The experimental subjects who were medicated first included those individuals 
planning to stop their SSRI medication with the consent of their doctor.   Cessation of 
SSRI therapy was a voluntary event uninfluenced by this research.   These subjects were 
tested first in a medicated condition.   The same individuals were re-tested when they 
ceased taking medication for at least one month. 
 All people expressing interest in participating in this research were screened using 
a standard questionnaire.   Their medication status, prescribing doctor, medical diagnosis, 
19
 
other medications currently taken, and history of hearing loss were all considered when 
selecting this group.   Cessation of any SSRI therapy was strictly voluntary and only 
subjects willing to be tested in both conditions were enrolled in the study.   None of the 
subjects expressing interest in participation were excluded from the study for any reason. 
 
Description of Experimental Procedures 
 Case History 
 Case history information was obtained from each subject prior to participation in 
test procedures.   The case history, information consisted of routine history generally 
used in audiology clinics.   In addition, it also included medical history such as history of 
depression and medications taken, audiologic history including hearing loss related to 
themselves and family members, and information regarding the prescribing physician of 
the SSRI.    
 Beck Depression Inventory-II 
 The Beck Depression Inventory-II is a self-questionnaire that addresses certain 
areas in a person’s life and how those aspects of their life may change according to their 
depressive state.   This 21-item inventory includes questions about sadness, guilty 
feelings, changes in sleeping and appetite, suicidal thoughts or wishes and other clinical 
symptoms of depression.   This inventory was given to all experimental and control 
subjects.   The BDI-II assesses how the person has been feeling for the last two weeks.   
The person evaluated is asked to circle the statement that best describes how they have 
been feeling for the last two weeks.   The values assigned to the statements were added 
together to obtain a raw score.   This score is then matched to a scale to assign a 
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particular level of depression; the highest score being 63 and the lowest being zero.   
According to this scale, a score of 0-12 indicates minimal depression, 13-19 indicated 
mild depression, 20-28 indicates moderate depression, and 29-63 indicates severe 
depression. 
Otoscopy 
 Otoscopy is a visual observation of the external auditory meatus (EAM) and the 
tympanic membrane with an otoscope.   The EAM was examined for excessive cerumen, 
foreign bodies, or any other abnormality.   The tympanic membrane was assessed for any 
discoloration, perforations, or other indicators of a compromised tympanic membrane. 
 Each subject began the test battery with otoscopy to ensure their ear canals were 
healthy and there was no evidence of infection or other disorders of the external auditory 
meatus or the tympanic membrane. 
 Pure-Tone Audiometry 
 All subjects were tested using the modified Hughson -Westlake method of testing 
auditory thresholds (Carhart and Jerger, 1959).   Thresholds were obtained at octave 
frequencies from 250 Hz to 8000 Hz.   Bone conduction testing was preformed for any 
frequency falling outside the normal range of 25dB except for 8000 Hz.   The Auricle 
(GN Otometrics, Bloomington, MN, USA) and the Orbiter 922 (GN Otometrics, 
Bloomington, MN, USA) were used for this procedure both using (Madsen, MX-41/AR, 





 Tympanometry was preformed on each subject.   Tympanograms give 
information about the integrity of the middle ear based on static compliance values.   
Tympanograms were classified according to Jerger (1970).   Tympanometry was 
preformed using the GSI-33 (Grason-Stradler, Madison, WI, USA) to measure the 
patient’s tympanic membrane mobility. 
Acoustic Reflex Thresholds (ART) 
 Acoustic reflex thresholds were tested on both ears using a Grason-Stradler GSI-
33 impedance bridge.   Ipsilateral and contralateral reflexes were tested at 500, 1000, and 
2000 Hz.   Presentation began at 70 dBHL and increased by 5dB until a response was 
obtained.   This measure was then repeated to obtain a response two out of three times.   
Presentation levels did not exceed 105 dB as to avoid potential noise induced hearing loss 
(Hunter et al., 1999).   No response observed at this intensity level was recorded as no 
response (NR).  Absent reflexes at 105 dB and recorded as NR were assigned arbitrary 
values of 115 dB to show the elevation or absence of the response.   
Amplitude Resolution  
 Amplitude resolution was assessed using the Tucker Davis psychoacoustic 
equipment (Tucker-Davis Technologies, Gainesville, FL, USA).   First, thresholds were 
obtained using the Hughson-Westlake procedure for 1000 Hz pure-tone.   Following this, 
the test level was set at 30 dBSL.   Two 1000 Hz, 500 ms tone pulses with a 200 ms 
interval were played binaurally in phase and began with the same intensity.   Gradually, 
the second tone of the series increased in intensity by 0.5 dB until the subject indicated a 
change in the two tones presented (Fastl and Schorn, 1981; Fastl and Zwicker, 1979).   
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When the second tone was perceived as different at least two times, the computer 
program decreased the tone by 0.5dB.   The subject continued responding by indicating if 
the two tones were same or different.   The equipment was programmed to change the 
second 1000Hz pulse tone by 0.5 dB, either increasing or decreasing in intensity 
depending on the subject’s response of same or different.   When the subject indicated the 
tone was different, the intensity of the tone decreased until the subject indicated the tones 
sound the same.    A reversal was counted when a listener reversed his/her judgment.   
The computer averaged the number of reversals over 60 trials to obtain the reversal 
average.    This indicated the average increase in decibel level for the person to notice a 
change in the amplitude of the stimulus.    
 Auditory Brainstem Response 
 The auditory brainstem response (ABR) was elicited using binaural alternating 
clicks at a rate of 21.1 per second using the Bio-logic Navigator System (Bio-Logic 
Systems, Corp., Mundelein, IL, USA).   Cup electrodes were placed at four different 
locations using the 10-20 international electrode system (Hall, 1990).   The non-inverting 
electrode was placed at FPz, the inverting electrode was placed at the nape of the neck, 
and the nasion was used for the grounding electrode placement.   Impedance was 
maintained at 1000 ohms for all subjects.    The stimulus was delivered binaurally using 
foam tipped insert earphones.   The responses were averaged over 1024 runs. 
 The protocol began at 70dBnHL and descended until threshold was reached.   
Thresholds were determined by a repeatable wave V at the lowest intensity.    Repeatable 
responses exhibiting good morphology and low artifacts were considered true responses 
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(Hall, 1990).   When threshold was reached the ABR recordings were made at 55 dBnSL.   
Each recording was repeated twice to ensure a true response. 
 The latencies and amplitudes for ABR peak V were measured.   Identification of 
waves were rechecked independently by another examiner. 
Auditory Late Response 
 The auditory late response used the same equipment procedures and equipment as 
the auditory brainstem response.   Stimuli used for the ALR included rarefacting tone 
burst at a rate of 1.1 per second.   Responses represent the average for 150 responses, and 
were repeated to ensure reliable and repeatable responses. 
 The ALR protocol included testing at 15, 25, 35, 45, and 55 dBnSL levels in a 
random order using the threshold from the ABR.   ALRs were repeated at each intensity 
to ensure a true response.   Subjects remained awake and alert throughout the course of 
the test.   Patients who were sleepy were not tested at that time and were rescheduled for 
a different time of the day when they were more alert. 
 The latency and amplitude measures were made for P2 and N1 components of the 






 The tests used for this research were chosen for their ease of administration as 
well as their reliability.   Each patient participated in the same protocol although tests 
were randomized to maintain effective research design.   Pure-tone audiometry, and 
acoustic reflexes used the bracketing procedure where two out of three responses were 
identified as threshold.   Amplitude resolution has an internal reliability calculated by 
reversals averaged over 60 trials.   Auditory evoked responses were measured using 
standard electrode placement and with electrode impedance at 1000 ohms.   The 
responses were measured over 1024 times for brainstem responses and 150 times for 
cortical responses.   Identification of waveforms were done by one researcher then 
checked by another who was unaware of the subject’s condition or group membership.    
Statistical Analysis 
Statistical analysis of this data was done using Statistics Program for Social 
Sciences (SPSS) software (SPSS, Inc., Chicago, IL, USA).   Mean and standard deviation 
values were obtained on all test scores.   Independent sample t-tests were used to compare 
the results between control and unmedicated groups, and between control and medicated 
groups.   Paired-comparison t-test was used to evaluate the differences between the 











RESULTS AND DISCUSSION 
Results 
The purpose of this study was to investigate the role of SSRI medication on the 
auditory system in subjects diagnosed with clinical depression. The measures 
investigated in this study included otoscopy, pure tone audiometry, tympanometry, 
acoustic reflex thresholds (ARTs), amplitude resolution, auditory brainstem response 
(ABR), auditory late response (ALR), and the Beck Depression Inventory-II (BDI-II). 
Thirty-five subjects participated in this research, 17 in the control group and 18 in the 
experimental group. The experimental group in this study participated in two rounds of 
testing which included a medicated condition and an unmedicated condition. The control 
group consisted of subjects not presenting with depression, nor had any history of an 
affective disorder, or treatment with SSRI medication. 
Otoscopy and Tympanometry 
Otoscopy revealed clear ear canals in all subjects. Tympanometry revealed Type 
A tympanograms in 33 of the 35 subjects included in this study suggesting normal middle 
ear function. Two subjects presented with Type Ad tympanograms, one in the control 
group and one in the experimental group. Review of the case history for both subjects 
revealed a history of middle ear infections as children with insertion of PE tubes during 
childhood in one of the subjects. However, upon inspection of pure tone audiometry, 
both of these subjects exhibited normal hearing with thresholds below 25 dBHL. 
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All subject included in this study had pure tone averages (PTA) below 25 dBHL 
which is within the normal range of hearing for adults (AAOO, 1979).  The mean age, 
and PTA for both experimental and control groups are listed in Table 1. Raw data for 
these results can be found in Table Appendix A. 
 
Table 1: Results of basic measures: age, otoscopy, tympanograms 
 




















Normal for all 
subjects 
Normal for all 
subjects 




All type A except 
for one subject with 
type Ad/Ad 
All type A except 
for one subject with 
type Ad/Ad 
All type A except 












Acoustic Reflex Thresholds 
 
 The acoustic reflex threshold (ART) measures the contraction of the stapedius 
muscle in the middle ear to sufficiently loud stimuli.   Contraction of the stapedius 
muscled was measured ipsilaterally and contralaterally for tones at 500, 1000, and 2000 
Hz.   Responses were recorded as threshold for the lowest intensity of a pure tone that 
brought about a change in compliance of 0.03 ohms.   Absent reflexes at the limit of 
testing 105 dB (Hunter et al., 1999) were recorded as no response (NR) and then assigned 
an arbitrary value of 115 dB to show the response as elevated.   This is likely to affect the 
means and standard deviations, either increasing or decreasing the values.   The 
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ipsilateral and contralateral values for individual frequencies were averaged separately 
for each ear. 
 Means and standard deviations for the averages of these specific conditions were 
calculated.   Table 2 shows the mean and standard deviation scores with the experimental 
group during medicated and unmedicated conditions as well as the scores from the 
control group.   (NR means NR @ 105dBHL) No significant differences were found 
between the groups for right or left ears (p> 0.05).  
 
Table 2: Averaged Acoustic Reflex Thresholds (dBHL) for control and experimental 
conditions (medicated and unmedicated) 
Ipsi= Ipsilateral, Contra = Contralateral 
 









































A paired-samples t-test between medicated and unmedicated conditions did not 
show significant differences for acoustic reflexes.  The p values for this comparison 
ranged for the right ear from 0.166-0.646 and for the left ear p values ranged between 






 Amplitude resolution, which measures a person’s ability to detect small changes 
in intensity, was measured in 0.5 dB steps.    Two 1000 Hz tone pulses with duration of 
500 ms separated by a 200ms interval of silence were played binaurally.   The subject’s 
indication of whether the tones were the same or different, helped determine the average 
intensity needed to discriminate a change in intensity.    
Table 3 shows the mean and standard deviation for these relationships between 
the control and experimental groups.   Significant differences were not observed between 
the control group and medicated group, nor were they observed for the control group and 
the unmedicated group.   The paired-samples t-test between the medicated and 
unmedicated group also showed no significant differences.    It was also noted that the 
unmedicated group had the widest standard deviation followed by the medicated group.   
Raw data for reversals can be found in Appendix D. 
 
Table 3: Reversals for the control group compared to experimental group. 
 
















Beck Depression Inventory-II 
 
 The Beck Depression Inventory-II (BDI-II) was used to assess the level of 
depression in each subject using the criteria mandated by the test.   According to this 
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criteria, a score of 0-12 indicates minimal depression, 13-19 indicates mild depression, 
20-28 indicates moderate depression, and 29-63 indicates severe depression.   All 
subjects in the control group and subjects in both conditions of the experimental group 
were given the BDI-II.    
Table 4 shows the relationships between the groups compared for level of 
depression.   Significant differences were observed between the control group and the 
experimental group in the medicated condition (p = 0.000) as well as between the control 
group and experimental group in the unmedicated group (p = 0.000).   Overall, the 
unmediated group showed the highest mean scores with a mean of 15.24 with and a range 
of 36.  Comparison between the medicated and unmedicated conditions, however, did not 
reveal significant differences (p > 0.05).  According to the scale the medicated and the 
unmediated group showed mild depression where the control group showed minimal 
depression.  Raw data for the BDI-II can be found in Appendix E. 
 
Table 4: Mean of BDI-II scores for all group comparisons 
 





Group Size N= 16 N= 17 N=17 











Auditory Brainstem Response 
 Peak V Latency 
The auditory brainstem response was measured to assess the integrity of the 
auditory pathway from the VIIIth nerve to the midbrain.  ABR thresholds for all subjects 
fell within normal limits (<20 dBnHL).  Amplitudes and latencies were measured at 
55dBnSL, for peak V which is generated at the level of the lateral lemniscus in humans.  
The control group was first compared to the experimental group.  No significant 
differences were observed for the latency of peak V at 55 dBnSL between the control 
group as compared to the medicated group, or the control group as compared with the 
unmedicated group.  Likewise, when the medicated condition of the experimental group 
was compared to the unmedicated condition no significant differences were observed.  
Table 5 shows the mean and standard deviation values for the latency of peak V.  Raw 
data for the latencies of ABR peak V can be found in Appendix F. 
 
Table 5: Mean Latencies for ABR Peak V 





Group Size N= 17 N= 18 N= 18 









 Amplitude of Peak V 
The amplitudes of ABR peak V at 55 dBnSL were also compared between 
groups.  No significant differences were found for the amplitudes between the control 
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group and the medicated group, or for the control group and unmedicated group.  When 
the two experimental conditions were compared no significant differences were found for 
the amplitude of peak V.  Table 6 shows the mean and standard deviation values for the 
amplitude of wave V.  Although the medicated and unmedicated groups showed larger 
amplitudes, no significant differences were observed for any of the groups.  Raw data for 
the amplitudes of ABR peak V can be found in Appendix F. 
 
Table 6: Mean Amplitudes for ABR Peak V 





Group Size N= 17 N= 18 N= 18 









Auditory Late Responses 
 The auditory late response (ALR) generated at the level of the primary auditory 
cortex occurs between 50-300 ms and is identified as P1, N1and P2 components.   
Latencies and amplitudes of these peaks were compared between medicated and 
unmedicated conditions as well as between the control and experimental groups.   The 
five intensities tested were 55dBnSL, 45dBnSL, 35dBnSL, 25dBnSL, and 15dBnSL. 
 Latency of P1 
 The latency of P1 was measured for all subjects at all five intensity levels.  The 
control group was first compared to the experimental group.  Independent sample t-test 
between the control and medicated group did not reveal any significant differences for 
any of the intensities.  When the control group was compared to the unmedicated group, 
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significant differences were not observed, however, the unmedicated group consistently 
had shorter latencies when compared to the control group.  The mean and standard 
deviation values for P1 latency can be viewed in Figure 1.   
 
 
























The latency of P1 was also compared between the two conditions within the 
experimental group.  Unmedicated subjects showed consistently shorter latencies at all 
intensities when compared to the medicated condition.  Paired comparison t-test between 
the medicated and unmedicated conditions revealed a significantly shorter latency for P1 




Amplitude of P1/N1 
 The amplitude of P1/N1 was measured for the five intensities that define the 
amplitude stimulus intensity function; 55dBnSL, 45dBnSL, 35dBnSL, 25dBnSL, and 
15dBnSL.  The independent t-test comparing the control group to the medicated 
condition did not reveal any significant differences at any of the intensities.  The 
independent t-test also did not reveal significant differences between the control group 
and the unmedicated group.  Paired-sample t-test of the experimental conditions did not 
reach significance for any of the intensities in the series.   
 
Table 7: P1/N1 Amplitude (µv) between control and experimental groups (medicated and 
unmedicated) 
 










































 Latency of N1 
The latency of N1 was measured for all five intensities as set forth in the protocol.   
Comparisons were first made between the control and experimental groups.  Figure 2 
shows the mean and standard deviation values for the latency of N1.  No significant 
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differences were observed for the control group and the medicated condition at any of the 
intensities.  Similarly, no significant differences were observed for the control group and 
unmedicated condition.   
 
























The latencies of N1 were compared within the experimental group using the 
paired-samples t-test.   Significant differences were not reached for any of the intensities 
tested, though consistently the unmedicated condition showed shorter latencies when 
compared to the medicated condition. 
 Amplitude of N1/P2 
  The amplitude of this peak was measured for all intensities from 55dBnSL 
to 15dBnSL and compared between control group and experimental group.  These 
independent samples t-test did not reveal significant differences between the control 
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group and the medicated condition.  Similarly, no significant difference was observed 
between the control group and the unmedicated group.  When the N1/P2 amplitude was 
compared between the medicated and unmedicated conditions, amplitudes for the 
unmedicated condition were greater than the medicated condition at all intensities tested 
except one (35dBnSL).   A paired comparison t-test showed significant difference only at 
45 dBnSL (p=0.008).  This is shown in Figure 3. 
 
































The amplitude/intensity growth between 15dBnSL and 55dBnSL is shown in 
Table 8 for all groups.  The unmedicated group showed a larger amplitude growth than 
the control group.  It was interesting to see that the same subjects while under SSRI 




Table 8: P1/N1 Amplitude growth (µv) between control and experimental groups 
(medicated and unmedicated) 
 





Group Size N= 17 N= 18 N= 18 
Difference 
55-15 dBnSL 





 The purpose of this research was to investigate the relationship between SSRI 
medication and auditory skills in clinically depressed subjects.  The tests used in this 
research included acoustic reflexes, amplitude resolution, ABR latencies and amplitude 
of peak V, ALR latencies of P1 and N1, and ALR amplitudes for P1/N1 and N1/P2.  The 
selection of tests was based on available clinical research of serotonin related disorders 
and the its relationship to auditory processing.  Other auditory measures such as pure tone 
thresholds and otoscopy were used to examine the sensitivity and integrity of the auditory 
system.   The BDI-II was used to assess the degrees of depression exhibited by 
experimental subjects as compared to the control group. 
All subjects in this research exhibited normal hearing.  All subjects exhibited 
normal type A tympanograms except for two subjects who showed type Ad 
tympanograms.  These subjects reported to have middle ear infections during childhood.  
Middle ear infections can sometimes cause excessive scarring of the tympanic membrane 
resulting in shallow tympanograms.  These infections can also cause thinning of the 
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tympanic membrane or monomeric membranes, which are more compliant and will result 
in type Ad tympanograms.   
The acoustic reflex pathway consists of some of the same auditory nuclei as the 
ABR pathway (Thompson, 1983) and therefore like the ABR, has a concentration of 
serotonergic fibers.  Hence, the ART was used to assess the involvement of serotonin at 
the level of the brainstem.  No significant differences were observed for acoustic reflex 
thresholds for any of the groups for ipsilateral or contralateral conditions.  Carney (2001) 
also showed no significant differences in her static group comparison study for the 
acoustic reflex threshold or any other measure involving the acoustic reflex arc pathway.  
SSRI did not appear to have any influence on the acoustic reflex thresholds.  Serotonin 
may not play a significant role at the level of the brainstem in humans. 
 In this study amplitude resolution did not show significant differences between 
any of the groups compared.  Carney (2001) showed in the static group comparison that 
ones ability to detect small changes in intensity was not affected by SSRI medication.    
The BDI-II revealed significant differences between the control group and 
experimental group in both conditions.  The unmedicated condition had worse scores 
when compared to any other group, though still only exhibiting mild depression.   The 
scores for the BDI-II did not differ significantly between the unmedicated and the 
medicated condition and in a few cases the scores for the medicated condition increased.. 
The latency and amplitude of ABR Peak V did not reveal significant differences 
for any of the groups compared.  Bishop (2001) also did not show significant differences 
between the static group comparison for ABR peak V for latency or amplitude.  Though 
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all subjects exhibited normal ABR thresholds based on Peak V amplitude and latency 
data, all groups showed an increase in amplitude as intensity increased. 
The latency of P1 was significantly shorter for the experimental condition as 
compared to the control group.  A pattern of consistently shorter latencies for all 
intensities tested as part of an intensity series in 10 dB steps from 15dBnSL- 55dBnSL 
was observed for the unmedicated condition as compared with the control condition.  
This pattern can also be seen when comparing the unmedicated condition to the control 
group.  Research by Concu et al. (1977) showed latencies in the early component evoked 
potentials in rats to decrease when levels of cerebral serotonin decreased.  Serotonin is a 
modulator in the auditory system and serves to fine tune sensory information in the 
afferent auditory pathway.  When the level of cerebral serotonin is decreased, a decrease 
in latency is also observed.  This is a result of less inhibition and consequently less 
control over the sensory input traveling along the auditory pathway.  In this study the 
experimental group showed a lengthening of the P1 latency with SSRI medication. 
Although significant differences were not obtained for the latency of N1, the 
pattern of shorter latencies for the unmedicated group as compared to the control group is 
distinct.  The N1 pattern of shorter latencies also is pronounced for the unmedicated 
group when compared to the medicated group.   Similar to the latency of P1, shorter 
transmissions speeds are attributed to less inhibition in the auditory pathway, and 
observed in cases with lower levels of serotonin.   
Significant differences were observed for the N1/P2 amplitude at 45dBnSL for 
the unmedicated group when compared to the control group.  It is evident from exploiting 
the difference in amplitudes between intensities that the subjects in the unmedicated 
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group exhibit a rapid increase in amplitude at the higher intensities.  An increase in 
amplitude due to stimulus intensity is also observed for the unmedicated group as 
compared to the control group suggesting less control of the inhibitory mechanism.   This 
is referred to as the amplitude-stimulus augmentation function as described by Hegerl and 
Juckel  (1993).  The amplitude stimulus intensity function has been debated to exist by 
several researchers (Hegerl & Juckel, 1993; Juckel et al., 1999) and argued not 
observable by others (Dierks et al., 1999; Debener et al., 2002).  It appears that serotonin 
is active in the auditory cortex and contributes to the amplitude stimulus intensity 
function.  Further, as suggested by Juckel et al. (1999) by identifying the augmenting 
effect of the N1/P2 component, patients exhibiting serotonin disorders could more 
efficiently and specifically be treated with regard to medication response rather than the 
trial and error approach currently practiced.  It appears more research in this area is 
necessary to further establish this landmark of the ALR. 
Some of these trends that do not reach significant differences may be due to the 
relatively small sample size.  Further, more defined trends might be observed by 
increasing the homogeneity of the groups by matching subjects by degrees of depression 
exhibited or specific medications taken.  It appears the only significant differences 
observed for the electrophysiology battery was above the level of the brainstem at the 
cortical level.  Serotonin may show effects at the cortical level and might not play a 
significant role in the peripheral auditory system, which explains why no significant 





 The purpose of this research was to investigate the effect of SSRI medication on 
the auditory system in clinically depressed subjects.  The tests used in this research are 
widely accepted clinical measures and have been used in other studies relevant to 
research related to disorders of serotonin.  This protocol consisted of basic auditory 
measures such as otoscopy, tympanometry, and pure tone audiometry, as well as more 
advanced measures, which included ART, amplitude resolution, ABR, and ALR.  The 
BDI-II was used in this research to establish degrees of depression exhibited by subjects 
in the experimental group.  Results from these test measures indicate a series of 
consistent trends and statistically significant differences for several of the tests.  The 
following statistically significant findings were observed: 
• The experimental group exhibited greater scores on the BDI-II than did the 
control group for both medicated and unmedicated conditions. 
• The unmedicated group had shorter latencies at 55 dBnSL for P1 of the ALR 
compared to the medicated group. 
• The unmedicated group exhibited greater amplitudes at 45 dBnSL than did the 
medicated group for the N1/P2 amplitude. 
The following trends were observed: 
• The unmediated group showed shorter latencies for ALR Peak P1 and N1, 
compared to the control and medicated group. 
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• The unmedicated condition of the experimental group showed a greater growth in 
amplitude for the N1/P2 component as compared to the control group and 
medicated condition. 
 
Results from this research indicate that SSRI medication influences auditory 
processing at a level superior to the brainstem.   This is indicative in the decrease in 
latencies of ALR P1 and N1 as well as an increase in amplitude at higher intensities for 
the unmedicated subjects.  Central serotonin in the unmedicated subjects may have been 
depleted resulting in less inhibition or control causing the amplitudes to augment and the 
latencies to decrease.   
42
 43
RECOMMENDATIONS FOR FUTURE RESEARCH 
Recommendations for future research include an increased sample size to further 
distinguish patterns seen between unmedicated and control groups as well as observed 
between medicated and unmedicated groups. Also recommended for future research for 
SSRI medication and auditory measures include a more homogenous sample that might 
include subjects taking the same SSRI and same dosages, or subjects matched for degree 
of depression as established by the BDI-II. The tests employed in this research are 
sensitive to subtle changes in the auditory system that may be more observable when 
variability between subjects is decreased by increasing the sample size and homogeneity 
of the groups. Refining these measures more and using them systematically in a 
psychiatric clinic could possibly help determine the efficacy of treatment in individuals 
taking SSRI medication. 
Also ear-specific measures were not obtained in most test measures, so it is 
recommended that ear-specific tests be carried out in the future. It is apparent that future 
research related to serotonin in the auditory system is warranted. However, because of 
the complicated nature of depression and other affective disorders coupled with the many 
roles serotonin plays in the body and nervous system, research designs must take into 






































 1 Subject number E-8 was not included in this research.
                                                 
 
Subject Number Age Avg PTA Tymps R/L SSRI Diagnosis Dosage Mg/Day
C1 24.00 5.00 A/A
C2 31.00 4.50 A/A
C3 22.00 7.50 Ad/Ad
C4 21.00 3.50 A/A
C5 23.00 3.50 A/A
C6 23.00 5.00 A/A
C7 23.00 2.00 A/A
C8 23.00 2.00 A/A
C9 32.00 0.00 A/A
C10 23.00 4.00 A/A
C11 23.00 1.50 A/A
C12 28.00 1.00 A/A
C13 34.00 0.00 A/A
C14 25.00 1.00 A/A
C15 24.00 3.00 A/A
C16 25.00 9.00 A/A
C17 25.00 4.00 A/A
E1- med 20.00 7.50 A/A Zoloft Depression 50 MG
E2-med 26.00 7.50 A/A Zoloft Depression 100 MG
E3-med 21.00 9.00 A/A Prozac Depression 40 MG
E4-med 21.00 6.00 A/A Zoloft Depression 50 MG
E5-med 32.00 1.50 A/A Zoloft Depression 100 MG
E6-med 27.00 20.00 A/A Zoloft Depression 50 MG
E7-med 29.00 6.00 A/A Prozac Depression 40 MG
E9-med 19.00 19.00 A/A Prozac Depression 20 MG
E10-med 18.00 2.00 Ad/Ad Prozac Depression 20 MG
E11-med 23.00 4.00 A/A Paxil Anxiety No Data
E12-med 19.00 3.00 A/A Prozac Depression 10 MG
E13-med 22.00 3.00 A/A Zoloft Depression 50 MG
E14-med 42.00 5.00 A/A Zoloft Depression 150 M
E15-med 23.00 17.00 A/A Prozac Depression 20 MG
E16-med 27.00 3.50 A/A Zoloft OCD/ADD unknown
E17-med 21.00 6.50 A/A Celexa Depression 10 MG
E18-med 58.00 18.35 A/A Prozac Depression 40 MG
E19-med 27.00 4.50 A/A Zoloft Depression 100 MG
E1-unmed 20.00 6.00 A/A
E2-unmed 26.00 3.00 A/A
E3-unmed 21.00 5.00 A/A
E4-unmed 21.00 4.00 A/A
E5-unmed 32.00 1.00 A/A
E6-unmed 27.00 21.00 A/A
E7-unmed 29.00 6.00 A/A
E9-unmed 19.00 22.50 A/A
E10-unmed 18.00 2.50 Ad/Ad
E11-unmed 23.00 5.00 A/A
E12-unmed 19.00 5.50 A/A
E13-unmed 22.00 2.50 A/A
E14-unmed 42.00 2.50 A/A
E15-unmed 23.00 17.00 A/A
E16-unmed 27.00 4.00 A/A
E17-unmed 27.00 7.00 A/A
E18-unmed 58.00 20.85 A/A











































































































Subject Number R- Ipsi .5K R- Ipsi 1K R-Ipsi 2K Avg R-Ipsi R-Contra .5K R-Contra 1K R-Contra 2K Avg R-Contra R-CP RCS RC Ipsi
C1 95.00 85.00 85.00 88.33 95.00 90.00 90.00 91.67 100.00 95.00 115.00
C2 85.00 80.00 85.00 83.33 100.00 90.00 95.00 95.00 105.00 90.00 110.00
C3 95.00 90.00 85.00 90.00 100.00 100.00 95.00 98.33 115.00 95.00 115.00
C4 95.00 85.00 90.00 90.00 100.00 90.00 95.00 100.00 80.00 110.00
C5 115.00 115.00 115.00 115.00 115.00 115.00 115.00 115.00 115.00 115.00 115.00
C6 85.00 85.00 85.00 85.00 95.00 90.00 95.00 93.33 80.00 95.00 105.00
C7 105.00 105.00 95.00 101.67 115.00 115.00 105.00 111.67 115.00 100.00 115.00
C8 85.00 85.00 80.00 83.33 100.00 100.00 85.00 95.00 85.00 90.00 100.00
C9 95.00 90.00 85.00 90.00 105.00 100.00 90.00 98.33 115.00 100.00 115.00
C10 115.00 105.00 105.00 108.33 115.00 115.00 115.00 115.00 115.00 115.00 115.00
C11 100.00 95.00 100.00 98.33 115.00 115.00 115.00 115.00 115.00 115.00 115.00
C12 90.00 90.00 95.00 91.67 100.00 95.00 100.00 98.33 105.00 105.00 115.00
C13 100.00 95.00 95.00 96.67 100.00 95.00 90.00 95.00 115.00 115.00 115.00
C14 85.00 80.00 90.00 85.00 100.00 90.00 90.00 93.33 100.00 90.00 110.00
C15 85.00 80.00 85.00 83.33 85.00 90.00 85.00 86.67 90.00 85.00 100.00
C16 105.00 100.00 105.00 103.33 115.00 115.00 115.00 115.00 115.00 110.00 115.00
C17 90.00 85.00 85.00 86.67 95.00 90.00 85.00 90.00 95.00 85.00 115.00
E1- med 105.00 95.00 110.00 103.33 110.00 95.00 105.00 103.33 115.00 115.00 115.00
E2-med 90.00 85.00 90.00 88.33 100.00 95.00 95.00 96.67 105.00 90.00 105.00
E3-med 90.00 90.00 95.00 91.67 100.00 95.00 95.00 96.67 115.00 115.00 115.00
E4-med 95.00 95.00 95.00 95.00 105.00 100.00 115.00 106.67 115.00 115.00 115.00
E5-med 115.00 115.00 115.00 115.00 115.00 115.00 115.00 115.00 115.00 115.00 115.00
E6-med 90.00 90.00 90.00 90.00 100.00 100.00 95.00 98.33 115.00 105.00 115.00
E7-med 100.00 100.00 100.00 100.00 105.00 105.00 95.00 101.67 115.00 105.00 115.00
E9-med 95.00 95.00 90.00 93.33 100.00 100.00 100.00 100.00 115.00 115.00 115.00
E10-med 85.00 85.00 100.00 90.00 115.00 115.00 115.00 115.00 90.00 90.00 115.00
E11-med 80.00 80.00 85.00 81.67 105.00 95.00 90.00 96.67 105.00 95.00 105.00
E12-med 95.00 95.00 90.00 93.33 105.00 95.00 90.00 96.67 100.00 100.00 115.00
E13-med
E14-med 85.00 85.00 90.00 86.67 95.00 90.00 90.00 91.67 115.00 105.00 115.00
E15-med 95.00 100.00 100.00 98.33 115.00 115.00 115.00 115.00 115.00 115.00 115.00
E16-med 95.00 95.00 95.00 95.00 115.00 100.00 100.00 105.00 115.00 115.00 115.00
E17-med 115.00 95.00 105.00 105.00 115.00 115.00 115.00 115.00 105.00 115.00 115.00
E18-med 85.00 85.00 85.00 85.00 90.00 85.00 80.00 85.00 90.00 80.00 110.00
E19-med 95.00 95.00 95.00 95.00 95.00 95.00 90.00 93.33 100.00 85.00 115.00
E1-unmed 90.00 85.00 100.00 91.67 95.00 85.00 90.00 90.00 115.00 115.00 115.00
E2-unmed 95.00 90.00 95.00 93.33 100.00 105.00 100.00 101.67 105.00 90.00 105.00
E3-unmed 90.00 95.00 95.00 93.33 100.00 100.00 95.00 98.33 115.00 115.00 115.00
E4-unmed 95.00 90.00 90.00 91.67 115.00 105.00 100.00 106.67 115.00 115.00 115.00
E5-unmed 115.00 105.00 105.00 108.33 115.00 105.00 105.00 108.33 115.00 115.00 115.00
E6-unmed 80.00 85.00 80.00 81.67 90.00 90.00 90.00 90.00 115.00 95.00 95.00
E7-unmed 115.00 100.00 105.00 106.67 115.00 105.00 100.00 106.67 115.00 115.00 115.00
E9-unmed 100.00 95.00 95.00 96.67 115.00 105.00 100.00 106.67 115.00 115.00 115.00
E10-unmed 105.00 85.00 115.00
E11-unmed 85.00 85.00 85.00 85.00 100.00 90.00 85.00 91.67 90.00 90.00 105.00
E12-unmed 95.00 90.00 85.00 90.00 100.00 95.00 90.00 95.00 95.00 90.00 105.00
E13-unmed 85.00 90.00 95.00 90.00 115.00 95.00 95.00 101.67 115.00 115.00 115.00
E14-unmed 85.00 85.00 85.00 85.00 95.00 85.00 90.00 90.00 110.00 105.00 115.00
E15-unmed 90.00 90.00 85.00 88.33 105.00 105.00 105.00 105.00 100.00 100.00 90.00
E16-unmed 95.00 95.00 95.00 95.00 115.00 100.00 95.00 103.33 115.00 105.00 105.00
E17-unmed 115.00 115.00 115.00 115.00 115.00 115.00 115.00 115.00 115.00 115.00 115.00
E18-unmed 85.00 85.00 90.00 86.67 90.00 85.00 80.00 85.00 95.00 85.00 110.00
E19-unmed 85.00 100.00 100.00 95.00 105.00 95.00 100.00 100.00 115.00 115.00 115.00
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Subject Number L- Ipsi .5K L- Ipsi 1K L-Ipsi 2K Avg L-Ipsi L-Contra .5K L-Contra 1K L-Contra 2K Avg L-Contra LCP LCS LC Ipsi
C1 90.00 90.00 90.00 90.00 95.00 100.00 95.00 96.67 100.00 95.00 115.00
C2 85.00 80.00 80.00 81.67 90.00 90.00 95.00 91.67 100.00 95.00 115.00
C3 100.00 100.00 105.00 101.67 115.00 115.00 115.00 115.00 115.00 115.00 115.00
C4 85.00 80.00 80.00 81.67 95.00 90.00 85.00 90.00 95.00 80.00 110.00
C5 105.00 100.00 105.00 103.33 115.00 115.00 115.00 115.00 115.00 105.00 105.00
C6 85.00 90.00 90.00 88.33 95.00 85.00 90.00 90.00 105.00 90.00 105.00
C7 85.00 80.00 85.00 83.33 105.00 90.00 85.00 93.33 100.00 90.00 105.00
C8 75.00 75.00 80.00 76.67 100.00 95.00 85.00 93.33 90.00 85.00 100.00
C9 115.00 115.00 115.00 115.00 115.00 115.00 115.00 115.00 115.00 115.00 115.00
C10 115.00 115.00 115.00 115.00 115.00 115.00 115.00 115.00 115.00 115.00 115.00
C11 95.00 100.00 105.00 100.00 115.00 115.00 100.00 110.00 115.00 115.00 115.00
C12 85.00 95.00 100.00 93.33 105.00 100.00 115.00 106.67 115.00 105.00 115.00
C13 95.00 95.00 95.00 95.00 115.00 105.00 115.00 111.67 115.00 115.00 115.00
C14 95.00 95.00 95.00 95.00 105.00 90.00 105.00 100.00 110.00 100.00 115.00
C15 90.00 95.00 90.00 91.67 105.00 105.00 105.00 105.00 115.00 115.00 115.00
C16 115.00 115.00 115.00 115.00 115.00 115.00 115.00 115.00 115.00 110.00 115.00
C17 90.00 85.00 85.00 86.67 95.00 90.00 90.00 91.67 90.00 105.00 115.00
E1- med 100.00 90.00 100.00 96.67 105.00 105.00 100.00 103.33 115.00 115.00 115.00
E2-med 90.00 90.00 90.00 90.00 95.00 90.00 95.00 93.33 110.00 90.00 115.00
E3-med 90.00 90.00 90.00 90.00 95.00 100.00 100.00 98.33 115.00 100.00 115.00
E4-med 95.00 95.00 100.00 96.67 105.00 115.00 115.00 111.67 115.00 115.00 115.00
E5-med 105.00 100.00 95.00 100.00 115.00 115.00 100.00 110.00 115.00 115.00 115.00
E6-med 80.00 80.00 85.00 81.67 85.00 90.00 90.00 88.33 100.00 90.00 105.00
E7-med 95.00 95.00 95.00 95.00 105.00 100.00 95.00 100.00 105.00 105.00 115.00
E9-med 95.00 95.00 90.00 93.33 100.00 100.00 100.00 100.00 115.00 115.00 115.00
E10-med 80.00 75.00 75.00 76.67 90.00 85.00 75.00 83.33 95.00 95.00 115.00
E11-med 85.00 85.00 85.00 85.00 90.00 90.00 90.00 90.00 90.00 90.00 105.00
E12-med 100.00 100.00 105.00 101.67 95.00 115.00 105.00 105.00 115.00 115.00 115.00
E13-med 90.00 90.00 95.00 91.67 100.00 90.00 95.00 95.00 110.00 100.00 115.00
E14-med 85.00 80.00 90.00 85.00 105.00 100.00 95.00 100.00 110.00 110.00 115.00
E15-med 115.00 115.00 105.00 111.67 115.00 115.00 115.00 115.00 115.00 115.00 115.00
E16-med 95.00 90.00 95.00 93.33 115.00 115.00 100.00 110.00 115.00 115.00 115.00
E17-med 100.00 100.00 100.00 100.00 115.00 105.00 100.00 106.67 115.00 100.00 115.00
E18-med 100.00 95.00 95.00 96.67 105.00 100.00 100.00 101.67 110.00 100.00 115.00
E19-med 95.00 95.00 95.00 95.00 100.00 100.00 100.00 100.00 115.00 100.00 115.00
E1-unmed 90.00 85.00 100.00 91.67 100.00 95.00 95.00 96.67 115.00 115.00 115.00
E2-unmed 90.00 85.00 95.00 90.00 100.00 95.00 95.00 96.67 110.00 90.00 115.00
E3-unmed 95.00 90.00 90.00 91.67 95.00 100.00 100.00 98.33 115.00 115.00 115.00
E4-unmed 95.00 95.00 95.00 95.00 115.00 115.00 115.00 115.00 115.00 115.00 115.00
E5-unmed 100.00 95.00 95.00 96.67 115.00 100.00 95.00 103.33 115.00 105.00 115.00
E6-unmed 85.00 80.00 85.00 83.33 90.00 95.00 90.00 91.67 115.00 95.00 100.00
E7-unmed 100.00 100.00 95.00 98.33 105.00 100.00 100.00 101.67 115.00 105.00 115.00
E9-unmed 100.00 95.00 100.00 98.33 105.00 105.00 100.00 103.33 115.00 115.00 115.00
E10-unmed 90.00 85.00 90.00 88.33 95.00 90.00 95.00 93.33
E11-unmed 85.00 85.00 80.00 83.33 90.00 85.00 80.00 85.00 90.00 85.00 105.00
E12-unmed 90.00 85.00 85.00 86.67 100.00 90.00 90.00 93.33 85.00 105.00 115.00
E13-unmed 90.00 90.00 95.00 91.67 115.00 95.00 90.00 100.00 115.00 105.00 115.00
E14-unmed 85.00 85.00 90.00 86.67 105.00 95.00 95.00 98.33 110.00 110.00 115.00
E15-unmed 80.00 80.00 80.00 80.00 90.00 85.00 85.00 86.67 90.00 90.00 85.00
E16-unmed 95.00 85.00 90.00 90.00 105.00 100.00 95.00 100.00 115.00 105.00 105.00
E17-unmed 115.00 115.00 115.00 115.00 115.00 115.00 115.00 115.00 115.00 115.00 115.00
E18-unmed 100.00 95.00 95.00 96.67 115.00 105.00 100.00 106.67 110.00 100.00 115.00















S u b je c t 
N u m b e r
R e v e rs a l 
A v e ra g e
C 1 3 .5 0
C 2 3 .8 8
C 3 3 .8 0
C 4 3 .4 0
C 5 2 .5 0
C 6 1 .6 3
C 7 1 .0 0
C 8 2 .0 0
C 9 2 .6 0
C 1 0 1 .9 0
C 1 1 3 .5 0
C 1 2 3 .5 0
C 1 3 0 .8 0
C 1 4 3 .5 0
C 1 5 3 .0 0
C 1 6 3 .7 8
C 1 7 3 .0 9
E 1 - m e d 4 .9 2
E 2 -m e d 2 .5 0
E 3 -m e d 1 .6 3
E 4 -m e d 2 .0 5
E 5 -m e d 3 .4 2
E 6 -m e d 0 .2 5
E 7 -m e d 0 .0 0
E 9 -m e d 1 .6 4
E 1 0 -m e d N o  D a ta
E 1 1 -m e d 5 .6 2
E 1 2 -m e d 2 .9 4
E 1 3 -m e d 1 .7 0
E 1 4 -m e d 2 .3 3
E 1 5 -m e d 3 .9 1
E 1 6 -m e d 1 .6 0
E 1 7 -m e d 1 .7 7
E 1 8 -m e d 1 .3 8
E 1 9 -m e d 3 .5 0
E 1 -u n m e d 3 .8 0
E 2 -u n m e d 0 .7 5
E 3 -u n m e d 4 .5 0
E 4 -u n m e d N o  D a ta
E 5 -u n m e d 3 .2 9
E 6 -u n m e d N o  D a ta
E 7 -u n m e d 0 .3 0
E 9 -u n m e d 0 .8 6
E 1 0 -u n m e d 3 .1 5
E 1 1 -u n m e d 6 .2 0
E 1 2 -u n m e d 0 .6 0
E 1 3 -u n m e d 9 .5 0
E 1 4 -u n m e d 1 .2 5
E 1 5 -u n m e d 3 .1 5
E 1 6 -u n m e d 1 .0 0
E 1 7 -u n m e d 2 .1 4
E 1 8 -u n m e d 0 .9 2










S u b j e c t  
N u m b e r B D I - I I
C 1 6 . 0 0
C 2 1 . 0 0
C 3 0 . 0 0
C 4 1 . 0 0
C 5 0 . 0 0
C 6 0 . 0 0
C 7 0 . 0 0
C 8 0 . 0 0
C 9 0 . 0 0
C 1 0 0 . 0 0
C 1 1 0 . 0 0
C 1 2 4 . 0 0
C 1 3 2 . 0 0
C 1 4 N o n e
C 1 5 3 . 0 0
C 1 6 5 . 0 0
C 1 7 1 . 0 0
E 1 -  m e d R e f u s e d
E 2 - m e d 1 4 . 0 0
E 3 - m e d 2 7 . 0 0
E 4 - m e d 6 . 0 0
E 5 - m e d 4 . 0 0
E 6 - m e d 1 3 . 0 0
E 7 - m e d 2 7 . 0 0
E 9 - m e d 1 1 . 0 0
E 1 0 - m e d 1 5 . 0 0
E 1 1 - m e d 1 9 . 0 0
E 1 2 - m e d 6 . 0 0
E 1 3 - m e d 5 . 0 0
E 1 4 - m e d 2 1 . 0 0
E 1 5 - m e d 2 . 0 0
E 1 6 - m e d 7 . 0 0
E 1 7 - m e d 8 . 0 0
E 1 8 - m e d 2 6 . 0 0
E 1 9 - m e d 2 9 . 0 0
E 1 - u n m e d R e f u s e d
E 2 - u n m e d 3 5 . 0 0
E 3 - u n m e d 1 0 . 0 0
E 4 - u n m e d 2 9 . 0 0
E 5 - u n m e d 2 0 . 0 0
E 6 - u n m e d 3 . 0 0
E 7 - u n m e d 3 7 . 0 0
E 9 - u n m e d 2 . 0 0
E 1 0 - u n m e d 3 9 . 0 0
E 1 1 - u n m e d 1 8 . 0 0
E 1 2 - u n m e d 3 . 0 0
E 1 3 - u n m e d 4 . 0 0
E 1 4 - u n m e d 5 . 0 0
E 1 5 - u n m e d 5 . 0 0
E 1 6 - u n m e d 1 0 . 0 0
E 1 7 - u n m e d 5 . 0 0
E 1 8 - u n m e d 2 6 . 0 0






















































































































C1 81.83 75.38 66.00 53.11
C2 64.52 71.86 81.24 71.86 63.66
C3 47.25 50.77 44.91 64.83 64.83
C4 69.52 68.35 74.21 70.69 83.58
C5 54.28 56.63 60.14 62.49 68.35
C6 64.83 66.00 70.69 67.18 62.49
C7 40.22 43.74 46.08 49.60 48.43
C8 54.29 56.63 63.66 63.66 81.24
C9 57.80 62.49 48.42 76.55 85.93
C10 36.70 41.39 46.08 44.91 48.43
C11 74.21 78.31 87.69 88.27 62.49
C12 42.56 43.74 42.56 58.97 53.11
C13 58.97 59.56 69.52 73.04 74.21
C14 59.56 61.32 60.14 69.52 61.32
C15 66.00 67.18 58.97 74.12 66.00
C16 47.25 63.66 64.83
C17 66.00 64.83 71.86 80.07 71.86
E1- med 39.64 46.08 71.86 68.35 70.69
E2-med 66.59 68.94 71.28 67.18 69.52
E3-med 71.28 71.86 63.66 67.18 69.52
E4-med 64.25 61.32 61.32 63.66 53.11
E5-med 57.21 56.63 51.94 54.87 48.42
E6-med 61.32 53.44 55.46 62.49 67.18
E7-med 81.83 82.41 87.10 74.21 89.44
E9-med 44.91 50.77 73.04 69.52 91.79
E10-med 63.66 60.73 58.98 61.94 61.91
E11-med 55.46 54.28 58.97 53.11 68.35
E12-med 73.04 67.18 90.62 68.35 58.97
E13-med 60.73 60.14 48.42 56.63 53.11
E14-med 58.97 62.49 62.49 63.66 67.18
E15-med 68.94 63.66 77.72 73.04 47.84
E16-med 57.87 42.56 47.25 40.22 63.66
E17-med 58.97 64.25 44.91 50.77 49.60
E18-med 70.69 69.52 69.52 75.38 77.72
E19-med 67.18 64.83 68.35 67.18 71.86
E1-unmed 40.22 41.39 54.28 58.97 62.49
E2-unmed 63.42 67.18 64.83 61.32 58.97
E3-unmed 58.66 60.14 58.97 74.21 70.69
E4-unmed 63.51 69.52 69.52 60.14 34.36
E5-unmed 40.22 50.77 50.77 58.97 53.11
E6-unmed 57.38 55.46 64.84 66.00 70.70
E7-unmed 72.45 70.69 66.00 67.18 85.93
E9-unmed 46.67 56.63 66.00 69.52 49.01
E10-unmed 53.08 63.66 63.08 57.80 63.66
E11-unmed 53.11 55.46 46.08 51.94 51.94
E12-unmed 63.66 92.96 75.38 69.52 99.99
E13-unmed 66.00 61.32 67.18 66.00 75.38
E14-unmed 43.74 50.77 47.25 56.63 49.60
E15-unmed 47.25 34.36 56.63 82.41
E16-unmed 45.50 46.08 50.77 56.63 42.56
E17-unmed 39.64 44.91 55.46 49.60 56.63
E18-unmed 47.25 47.25 51.94 56.63
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